Prelude Therapeutics Receives FDA IND Clearance for PRT13722
Prelude Therapeutics announced FDA clearance for a Phase 1 study of oral degrader PRT13722 in HR+ breast cancer, with anticipated enrollment starting in Q4 2026. This regulatory milestone supports the company's specific approach to a validated oncology target, expanding its precision medicine pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day